

<p><u>PLEASE READ</u></p> <p>IMPORTANT MEDICINE SAFETY INFORMATION</p>	<p>APPROVED BY THE</p> <p>HPRA An tÚdarás Rialála Táirgí Sláinte Health Products Regulatory Authority</p>
--	--



24th December 2025

Carbamazepine (Tegretol 100 mg/5ml Oral Suspension); restriction of use in neonates as concentration of the excipient, propylene glycol, exceeds recommended threshold

Dear Healthcare Professional,

Novartis Ireland Limited in agreement with the Health Products Regulatory Authority would like to inform you of the following:

Summary

- Tegretol (carbamazepine) 100 mg/5ml Oral Suspension (OS) **should not be used in neonates below 4 weeks of age (or 44 weeks post-menstrual age for pre-term babies).**
- This is because of the amount of propylene glycol in the product, which may lead to serious adverse reactions such as metabolic acidosis, renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.
- The only exception is if no other treatment option is available and the expected benefit outweighs the risks. In such case, medical monitoring, including measurements of osmolar and/or anion gap, is recommended.
- If other carbamazepine oral suspensions without propylene glycol are available, they are not affected by this restriction of use.

Background on the safety concern

Tegretol (carbamazepine) 100 mg/5ml OS is indicated for the treatment of various conditions including epilepsy (generalised tonic-clonic and partial seizure types).

The concentration of propylene glycol, an excipient used in this formulation, is 25 mg/1 mL, which exceeds the recommended threshold for neonates of 1 mg/kg/day.

In neonates, doses of propylene glycol ≥ 1 mg/kg/day accumulate in the body due to immaturity of metabolic and renal clearance pathways of propylene glycol. This may lead to serious adverse reactions such as metabolic acidosis, renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.

Therefore, Tegretol 100 mg/5ml Oral Suspension should not be used in neonates below 4 weeks of age for term babies (or 44 weeks post-menstrual age for pre-term babies). The only exception is if no other treatment option is available and the expected benefit outweighs the risks, also considering the risks associated with the excipients.

Medical monitoring, including measurements of osmolar and/or anion gap, is recommended in neonates below 4 weeks of age who are receiving treatment with Tegretol 100 mg/ 5 ml Oral Suspension. Co-administration with other medicinal products containing propylene glycol or with any substrate of alcohol dehydrogenase such as ethanol increases the risk of propylene glycol accumulation and toxicity. The ethylene and diethylene glycol present in the product is also substrates of alcohol dehydrogenase.

The product information is being updated to reflect this limitation of use in neonates and to inform about the risk posed by the excipient content of the product.

For children above 4 weeks of age (or 44 weeks post menstrual age for preterm babies), there are no changes to the label recommendations. This update only affects Tegretol 100 mg/5ml Oral Suspension; no other Tegretol formulations or carbamazepine-containing products are impacted.

Call for reporting

Healthcare professionals are asked to report any suspected adverse drug reactions via HPRA Pharmacovigilance, website: www.hpra.ie and include batch/Lot number if available.

Company contact point

For further inquiries please email medinfo.dublin@novartis.com or contact Novartis Ireland at the following address:

Novartis Ireland Limited
Vista Building
Elm Park Business Campus
Merrion Road
Dublin 4
Ireland
D04A9N6
Tel: + 353 1 220 4100

Yours sincerely,

Signed by:

Agron Hasani

0125C2AA6DF64A1...

Agron Hasani M.D.
Country Head of Medical Affairs/Chief Medical Officer
Novartis Ireland Limited